

# Press Release



## Notice of Revisions of Dividends from Surplus (Increase in Interim Dividend) and Year-end Dividend Forecast

**TOKYO, November 6, 2023** – ASKA Pharmaceutical Holdings Co., Ltd. (Head Office: Minato-ku, Tokyo/ President, Representative Director: Takashi Yamaguchi) announced that the Company has resolved at the board meeting held today to pay an interim dividend from a surplus with a record date of September 30, 2023, and to revise its year-end dividend forecast for the fiscal year ending March 31, 2024, as follows.

### 1. Details of Dividends from Surplus (Interim Dividends)

	Amount	Previous Forecast (Announced on May 11, 2023)	Actual FY2022
Reference Date	September 30, 2023	Same as on the left	September 30, 2022
Dividend per share	20.00 yen	10.00 yen	8.00 yen
Total amount of dividends	566 million yen	-	226 million yen
Effective date	November 30, 2023	-	November 30, 2022
Dividend resource	Retained earnings	-	Retained earnings

### 2. Details of Revision of Dividend Forecast

Dividend forecast for the fiscal year ending March 31, 2024

	Annual dividend per share		
	End of 2nd quarter	Year-end	Annual
Previous Forecast (Announced on May 11, 2023)	Yen 10.00	Yen 10.00	Yen 20.00
Revised Forecast		20.00	40.00
Actual FY2023	20.00		
Actual FY2022	8.00	8.00	16.00

### 3. Reason for the Revisions

The Company recognizes the stable return of profits to shareholders as one of its highest management priorities. Our basic policy is to distribute profits while comprehensively taking into account consolidated business performance and medium- to long-term capital needs while making strategic capital investments and strengthening our financial position in preparation for future business development. Based on this policy, in light of the upward revision of the earnings forecast for the fiscal year ending March 31, 2024, announced on September 25, 2023, due to the recording of a gain on sales of investment securities, as well as the results for the second quarter of the fiscal year ending March 31, 2024, announced today, the interim dividend is 20 yen per share. The year-end dividend forecast is also revised to 20 yen per share. Therefore, the annual dividend per share will be 40 yen.

(NOTE) The above forecasts are based on information available as of the date of announcement and are inherently subject to various uncertainties, which may cause actual dividend amounts to differ.

---

### Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.

Corporate Planning Department

Tel: +81-3-5484-8366

Email: [kouhou@aska-pharma.co.jp](mailto:kouhou@aska-pharma.co.jp)